239 related articles for article (PubMed ID: 34240815)
1. Establishment of patient-derived organotypic tumor spheroid models for tumor microenvironment modeling.
Hong HK; Yun NH; Jeong YL; Park J; Doh J; Lee WY; Cho YB
Cancer Med; 2021 Aug; 10(16):5589-5598. PubMed ID: 34240815
[TBL] [Abstract][Full Text] [Related]
2.
Jenkins RW; Aref AR; Lizotte PH; Ivanova E; Stinson S; Zhou CW; Bowden M; Deng J; Liu H; Miao D; He MX; Walker W; Zhang G; Tian T; Cheng C; Wei Z; Palakurthi S; Bittinger M; Vitzthum H; Kim JW; Merlino A; Quinn M; Venkataramani C; Kaplan JA; Portell A; Gokhale PC; Phillips B; Smart A; Rotem A; Jones RE; Keogh L; Anguiano M; Stapleton L; Jia Z; Barzily-Rokni M; Cañadas I; Thai TC; Hammond MR; Vlahos R; Wang ES; Zhang H; Li S; Hanna GJ; Huang W; Hoang MP; Piris A; Eliane JP; Stemmer-Rachamimov AO; Cameron L; Su MJ; Shah P; Izar B; Thakuria M; LeBoeuf NR; Rabinowits G; Gunda V; Parangi S; Cleary JM; Miller BC; Kitajima S; Thummalapalli R; Miao B; Barbie TU; Sivathanu V; Wong J; Richards WG; Bueno R; Yoon CH; Miret J; Herlyn M; Garraway LA; Van Allen EM; Freeman GJ; Kirschmeier PT; Lorch JH; Ott PA; Hodi FS; Flaherty KT; Kamm RD; Boland GM; Wong KK; Dornan D; Paweletz CP; Barbie DA
Cancer Discov; 2018 Feb; 8(2):196-215. PubMed ID: 29101162
[No Abstract] [Full Text] [Related]
3. PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures.
Appleton KM; Elrod AK; Lassahn KA; Shuford S; Holmes LM; DesRochers TM
Cancer Immunol Immunother; 2021 Mar; 70(3):843-856. PubMed ID: 33492447
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line.
Pyo DH; Hong HK; Lee WY; Cho YB
Cancer Biol Ther; 2020 Jun; 21(6):495-502. PubMed ID: 32208894
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of PD‑L1 in colorectal cancer (Review).
Ntomi V; Foukas P; Papaconstantinou D; Antonopoulou I; Pikoulis A; Panagiotides I; Pikoulis E; Syrigos K
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846789
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
7. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
8. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
9. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
[TBL] [Abstract][Full Text] [Related]
10. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
11. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
13. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
15. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
Cao Y; Li W; Wang Z; Pang H
Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
17. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
18. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
Front Immunol; 2021; 12():619209. PubMed ID: 33790893
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
20. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment.
Yu G; Wu Y; Wang W; Xu J; Lv X; Cao X; Wan T
Cell Mol Immunol; 2019 Apr; 16(4):401-409. PubMed ID: 29622799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]